



Jfw

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL  
FORM**

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

11

Application Number

10/810,751

Filing Date

03/26/2004

First Named Inventor

David S. F. Young

Art Unit

1642

Examiner Name

Attorney Docket Number

2056.039

**ENCLOSURES (Check all that apply)**

- |   |   |   |
|---|---|---|
| <input type="checkbox"/> Fee Transmittal Form                             | <input type="checkbox"/> Drawing(s)                                       | <input type="checkbox"/> After Allowance Communication to TC                            |
| <input type="checkbox"/> Fee Attached                                     | <input type="checkbox"/> Licensing-related Papers                         | <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences     |
| <input type="checkbox"/> Amendment/Reply                                  | <input type="checkbox"/> Petition   | <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) |
| <input type="checkbox"/> After Final                                      | <input type="checkbox"/> Petition to Convert to a Provisional Application | <input type="checkbox"/> Proprietary Information  |
| <input type="checkbox"/> Affidavits/declaration(s)                        | <input type="checkbox"/> Power of Attorney, Revocation                    | <input type="checkbox"/> Status Letter  |
| <input type="checkbox"/> Extension of Time Request                        | <input type="checkbox"/> Change of Correspondence Address                 | <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):         |
| <input type="checkbox"/> Express Abandonment Request                      | <input type="checkbox"/> Terminal Disclaimer                              | Copies of (60) references   |
| <input checked="" type="checkbox"/> Information Disclosure Statement      | <input type="checkbox"/> Request for Refund                               |   |
| <input type="checkbox"/> Certified Copy of Priority Document(s)           | <input type="checkbox"/> CD, Number of CD(s) _____                        |   |
| <input type="checkbox"/> Reply to Missing Parts/Incomplete Application    | <input type="checkbox"/> Landscape Table on CD                            |   |
| <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53 |   |   |

Remarks

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Firm Name

McHale &amp; Slavin, P.A.

Signature

Printed name

Ferris H. Lander

Date

6/27/2005

Reg. No.

43,377

**CERTIFICATE OF TRANSMISSION/MAILING**

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature

Typed or printed name

Debra N. Gerstemeier

Date

6-27-2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICANT : David S. F. Young et al  
INVENTION : CYTOTOXICITY MEDIATION OF CELLS  
EVIDENCING SURFACE EXPRESSION OF CD63  
SERIAL NUMBER : 10/810,751  
FILING DATE : March 26, 2004  
EXAMINER :  
GROUP ART UNIT : 1642  
ATTORNEY DOCKET NO. : 2056.039

---

CERTIFICATE UNDER 37 CFR §1.8(a)  
I hereby certify that this correspondence is being deposited with  
the U.S. Postal Service as First Class mail in an envelope  
addressed to Commissioner for Patents, P.O. Box 1450,  
Alexandria, VA 22313-1450 on 6-27-2005

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Pursuant to the duty of disclosure under 37 CFR §1.56, the references cited on the accompanying forms PTO/SB/08A and PTO/SB/08B are hereby brought to the attention of the Examiner for independent evaluation. Copies of those references previously made of record in parent U. S. Patent Application No. 10/603,006, filed June 23, 2003, upon which the present application claims priority under 35 USC §120, have not been included pursuant to 37 CFR §1.98(d). Copies of the newly-cited references for the above application have been included.

Applicants submit that the present invention is patentable over the cited references.

Date 6/27/2005

Respectfully submitted,

By Ferris H. Lander  
Ferris H. Lander  
Registration No. 43,377  
McHale & Slavin, P.A.  
2855 PGA Boulevard  
Palm Beach Gardens, FL 33410  
Telephone: (561) 625-6575  
Facsimile: (561) 625-6572



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Patent Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/810,751
Filing Date	03/26/2004
First Named Inventor	David S. F. Young
Art Unit	1642
Examiner Name	
Attorney Docket Number	2056.039

Sheet 1 of 9

**U. S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
		US- 4,861,581	08/29/1989	Epstein et al	
		US- 5,171,665	12/15/1992	Hellstrom et al	
		US- 5,484,596	01/16/1996	Hanna, Jr., et al	
		US- 5,693,763	12/02/1997	Codington et al	
		US- 5,750,102	05/12/1998	Eisenbach et al	
		US- 5,780,033	07/14/1998	Torchilin et al	
		US- 5,783,186	07/21/1998	Arakawa et al	
		US- 5,849,876	12/15/1998	Linsley et al	
		US- 5,869,045	02/09/1999	Hellstrom et al	
		US- 5,869,268	02/09/1999	Kudo et al	
		US- 6,180,357	01/30/2001	Young et al	
		US- 5,296,348	03/22/1994	Rakowicz-Szulczynska et al	
		US- 2004/0105816A1	06/03/2004	Young et al	
		US- 2003/0211498A1	11/13/2003	Morin et al	
		US- 2004/0141913A1	07/22/2004	Young et al	
		US- 2004/0141915A1	07/22/2004	Young et al	
		US-			
		US-			
		US-			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
		WO01/075177	10/11/2001	The Government of the United States		<input checked="" type="checkbox"/>
				of America, as represented by the		<input type="checkbox"/>
				Secretary, Dept Health & Human Services		<input type="checkbox"/>
		WO02/55551	07/18/2002	Shanghai Biowindow Gene Development Inc		<input type="checkbox"/>
		CN1364803A	08/21/2002	Shanghai Biowindow Gene Development Inc		<input type="checkbox"/>
		CN1326962A	12/19/2001	Shanghai Bode Gene Development Co Ltd		<input type="checkbox"/>

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Complete if Known**

(Use as many sheets as necessary)

Sheet	2	of	9
-------	---	----	---

Application Number	10/810,751
Filing Date	03/26/2004
First Named Inventor	David S. F. Young
Art Unit	1642
Examiner Name	
Attorney Docket Number	2056.039

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>o</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
		CN1326951A	12/19/2001	Shanghai Bode Gene Development Co Ltd		✓
		CN1351054A	05/29/2002	Shanghai Bode Gene Development Co Ltd		

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

*If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.*

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/810,751
				Filing Date	03/26/2004
				First Named Inventor	David S. F. Young
				Art Unit	1642
				Examiner Name	
Sheet	3	of	9	Attorney Docket Number	2056.039

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		T. KARPANEN et al, "Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth", Cancer Research, 61:1786-1790 (March, 2001)	
		W. WAUD et al, "Characterization of in vivo mammary and prostate tumor xenograft models for growth and response to clinical anticancer agents", Contrib Oncol Basel Karger, 54:305-315 (1999)	
		G. KLEMENT et al, "Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts", Clinical Cancer Research, 8:221-232 (January, 2002)	
		D. BLAKEY et al, "Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models", Clinical Cancer Research, 8:1974-1983 (June, 2002)	
		Z. XIAO et al, "Generation of a baculovirus recombinant prostate-specific membrane antigen and its use in the development of a novel protein biochip quantitative immunoassay", Protein Expression and Purification, 19:12-21 (2000)	
		S. Guichard et al, "Schedule-dependent activity of topotecan in OVCAR-3 ovarian carcinoma xenograft: pharmacokinetic and pharmacodynamic evaluation", Clinical Cancer Research, 7:3222-3228 (October, 2001)	
		V. VON GRUENIGEN et al, "Efficacy of intraperitoneal adenovirus-mediated p53 gene therapy in ovarian cancer", Int. J. Gynecol. Cancer, 9:365-372 (1999)	
		N. GUILBAUD et al, "Marked antitumor activity of a new potent acronycine derivative in orthotopic models of human solid tumors", Clinical Cancer Research, 7:2573-2580 (August, 2001)	
		K. OLSON et al, "Inhibition of prostate carcinoma establishment and metastatic growth in mice by an antiangiogenin monoclonal antibody", Int. J. Cancer, 98:923-929 (2002)	
		S. HIRSCHFELD et al, "Oncology drug development: United States Food and Drug Administration perspective", Critical Reviews in Oncology/Hematology, 42:137-143 (2002)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>		<b>Complete if Known</b>			
		Application Number	10/810,751		
		Filing Date	03/26/2004		
		First Named Inventor	David S. F. Young		
		Art Unit	1642		
		Examiner Name			
Sheet	4	of	9	Attorney Docket Number	2056.039

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		P. THERASSE et al, "New guidelines to evaluate the response to treatment in solid tumors", Journal of the National Cancer Institute, 92(3):205-216 (February, 2000)	
		G. ECKHARDT et al, "Developmental therapeutics: successes and failures of clinical trial designs of targeted compounds", in American Society of Clinical Oncology, pp. 209-219 (2003)	
		P. SMITH et al, "Anti-interleukin-6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice", The Prostate, 48:47-53 (2001)	
		M. MARTINEZ-LORENZO et al, "Unusual intracellular trafficking of salmonella typhimurium in human melanoma cells", Cellular Microbiology, 3(6):407-416 (2001)	
		H. OKOCHI et al, "Expression of tetra-spans transmembrane family (CD9, CD37, CD53, CD63, CD81 and CD82) in normal and neoplastic human keratinocytes: an association of CD9 with alpha3beta1 integrin", British Journal of Dermatology, 137:856-863 (1997)	
		J-M. ESCOLA et al, "Selective enrichment of tetraspan proteins on the internal vesicles of multivesicular endosomes and on exosomes secreted by human B-lymphocytes", J. Biol. Chem., 273(32):20121-20127 (August, 1998)	
		A. ENGERING et al, "Association of distinct tetraspanins with MHC class II molecules at different subcellular locations in human immature dendritic cells", International Immunology, 13(2):127-134 (2001)	
		P. SINCOCK et al, "Localization of the transmembrane 4 superfamily (TM4SF) member PETA-3 (CD151) in normal human tissues: comparison with CD9, CD63, and alpha5beta1 integrin", J. Histochem Cytochem, 45:515-525 (1997)	
		F. BERDITCHEVSKI et al, "Characterization of integrin-tetraspanin adhesion complexes: role of tetraspanins in integrin signaling", J. Cell Biol., 146(2):477-492 (July, 1999)	
		R. YAUCH et al, "Specific interactions among transmembrane 4 superfamily (TM4SF) proteins and phosphoinositide 4-kinase", Biochem. J., 351:629-637 (2000)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Sheet	5	of	9	Application Number	10/810,751
				Filing Date	03/26/2004
				First Named Inventor	David S. F. Young
				Art Unit	1642
				Examiner Name	
				Attorney Docket Number	2056.039

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		A. ZANNETTINO et al, "Molecular cloning of the cell surface antigen identified by the osteoprogenitor-specific monoclonal antibody, HOP-26", J. Cell. Biochem., 89:56-66 (2003)	
		C. JOYNER et al, "Identification and enrichment of human osteoprogenitor cells by using differentiation stage-specific monoclonal antibodies", Bone, 21(1):1-6 (July, 1997)	
		D. AZORSA et al, "A general approach to the generation of monoclonal antibodies against members of the tetraspanin superfamily using recombinant GST fusion proteins", J. Immunol. Meth., 229:35-48 (1999)	
		T. MARTIN, "Phosphoinositide lipids as signaling molecules: common themes for signal transduction, cytoskeletal regulation, and membrane trafficking", Annu. Rev. Cell Dev. Biol., 14:231-264 (1998)	
		J. HILDRETH et al, "Characterization of a novel self-associating Mr 40,000 platelet glycoprotein", Blood, 77 (1):121-132 (January, 1991)	
		R. STEPHEN et al, "A novel oestrogen-regulated gene in human breast cancer cells identified by differential display", J. Mol. Endocrin., 20:375-380 (1998)	
		G. ANDREOLA et al, "Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles", J. Exp. Med., 195(10):1303-1316 (May, 2002)	
		H-I. JANG et al, "A decrease in the expression of CD63 tetraspanin protein elevates invasive potential of human melanoma cells", Experimental and Molecular Medicine, 35(4):317-323 (August, 2003)	
		S. LEBEL-BINAY et al, "CD82, member of the tetra-span-transmembrane protein family, is a costimulatory protein for T cell activation", J. Immunol., 155:101-110 (1995)	
		C. HUANG et al, "Correlation of reduction in MRP-1/CD9 and KAI1/CD82 expression with recurrences in breast cancer patients", Am J Pathol, 153(3):973-983 (September, 1998)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/810,751
				Filing Date	03/26/2004
				First Named Inventor	David S. F. Young
				Art Unit	1642
				Examiner Name	
Sheet	6	of	9	Attorney Docket Number	2056.039

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		P. PETERS et al, "Cytotoxic T lymphocyte granules are secretory lysosomes, containing both perforin and granzymes", J. Exp. Med., 173:1099-1109 (May, 1991)	
		B. MANNION et al, "Transmembrane-4 superfamily proteins CD81 (TAPA-1), CD82, CD63, and CD53 specifically associate with integrin alpha4beta1 (CD49d/CD29)", J. Immunol., 157:2039-2047 (1996)	
		Y. KOYAMA et al, "CD63, a member of tetraspan transmembrane protein family, induces cellular spreading by reaction with monoclonal antibody on substrata", Biochem Biophys Res Comm, 246(3):841-846 (1998)	
		K. RADFORD et al, "Regulation of tumor cell motility and migration by CD63 in a human melanoma cell line", J. Immunol., 158:3353-3358 (1997)	
		J. LI et al, "Recombinant CD63/ME491/neuroglandular/NK1/C-3 antigen inhibits growth of established tumors in transgenic mice", J. Immunol., 171:2922-2929 (2003)	
		M. METZELAAR et al, "CD63 antigen", J. Biol. Chem., 266(5):3239-3245 (February, 1991)	
		A. ZANNETTINO et al, "A powerful new technique for isolating genes encoding cell surface antigens using retroviral expression cloning", J. Immunol., 156:611-620 (1996)	
		V. TOOTHILL et al, "Characterization of the enhanced adhesion of neutrophil leukocytes to thrombin-stimulated endothelial cells", J. Immunol., 145(1):283-291 (July, 1990)	
		T. KOBAYASHI et al, "The tetraspanin CD63/lamp3 cycles between endocytic and secretory compartments in human endothelial cells", Molecular Biology of the Cell, 11:1829-1843 (May, 2000)	
		K. SKUBITZ et al, "CD63 associates with tyrosine kinase activity and CD11/CD18, and transmits an activation signal in neutrophils", J. Immunol., 157:3617-3626 (1996)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)	<b>Application Number</b>		10/810,751		
	<b>Filing Date</b>		03/26/2004		
	<b>First Named Inventor</b>		David S. F. Young		
	<b>Art Unit</b>		1642		
	<b>Examiner Name</b>				
<b>Sheet</b>	7	<b>of</b>	9	<b>Attorney Docket Number</b>	2056.039

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		F. BERDITCHEVSKI et al, "A novel link between integrins, transmembrane-4 superfamily proteins (CD63 and CD81), and phosphatidylinositol 4-kinase", J. Biol. Chem., 272(5):2595-2598 (January, 1997)	
		F. BERDITCHEVSKI et al, "Specific association of CD63 with the VLA-3 and VLA-6 integrins", J. Biol. Chem., 270(30):17784-17790 (July, 1995)	
		K. SKUBITZ et al, "CD63 associates with CD11/CD18 in large detergent-resistant complexes after translocation to the cell surface in human neutrophils", FEBS Letters, 469:52-56 (2000)	
		K. RADFORD et al, "CD63 associates with transmembrane 4 superfamily members, CD9 and CD81, and with beta1 integrins in human melanoma", Biochem Biophys Res Comm, 222:13-18 (1996)	
		C. CLAAS et al, "Evaluation of prototype transmembrane 4 superfamily protein complexes and their relation to lipid rafts", J. Biol. Chem., 276(11):7974-7984 (March, 2001)	
		C. HAMMOND et al, "The tetraspan protein CD82 is a resident of MHC class II compartments where it associates with HLA-DR, -DM, and -DO molecules", J. Immunol, 161:3282-3291 (1998)	
		D. DEMETRICK et al, "ME491 melanoma-associated glycoprotein family: antigenic identity of ME491, NKI/C-3, neuroglandular antigen (NGA), and CD63 proteins", J. Natl Cancer Inst, 84(6):422-429 (March, 1992)	
		C. VENNEGOOR et al, "Circulating melanoma-associated antigen detected by monoclonal antibody NKI/C-3", Cancer Immunol Immunother, 23:93-100 (1986)	
		M. WANG et al, "An ocular melanoma-associated antigen", Arch Ophthalmol., 110:399-404 (1992)	
		B. ULBRICHT et al, "Influence of 12(S)-hydroxyeicosatetraenoic acid (12(S)-HETE) on the localization of cathepsin B and cathepsin L in human lung tumor cells", Eur J Cell Biol, 74:294-301 (November, 1997)	

**Examiner  
Signature****Date  
Considered**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

**Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>		<b>Complete if Known</b>			
		Application Number	10/810,751		
		Filing Date	03/26/2004		
		First Named Inventor	David S. F. Young		
		Art Unit	1642		
		Examiner Name			
Sheet	8	of	9	Attorney Docket Number	2056.039

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		M. BARRIO et al, "Monoclonal antibody FC-5.01, directed against CD63 antigen, is internalized into cytoplasmic vesicles in the IIB-BR-G human breast cancer cell line", Hybridoma, 17(6):517-523 (1998)	
		M. ADACHI et al, "Novel staging protocol for non-small-cell lung cancers according to MRP-1/CD9 and KAI1/CD82 gene expression", J. Clin. Oncol., 16(4):1397-1406 (April, 1998)	
		E. RUBINSTEIN et al, "CD9, CD63, CD81, and CD82 are components of a surface tetraspan network connected to HLA-DR and VLA integrins", Eur. J. Immunol., 26:2657-2665 (1996)	
		H. HOTTA et al, "Genomic structure of the ME491/CD63 antigen gene and functional analysis of the 5'-flanking regulatory sequences", Biochem Biophys Res Comm, 185(1):436-442 (May, 1992)	
		Y. KOYAMA et al, "A novel monoclonal antibody induces the differentiation of monocyte leukemic cells", Biochem Biophys Res Comm, 168(3):898-904 (May, 1990)	
		A. CARMO et al, "Association of the transmembrane 4 superfamily molecule CD53 with a tyrosine phosphatase activity", Eur. J. Immunol., 25:2090-2095 (1995)	
		M. BARRIO et al, "A new epitope on human melanoma-associated antigen CD63/ME491 expressed by both primary and metastatic melanoma", Hybridoma, 17(4):355-364 (1998)	
		Z. SI et al, "Expression of the neuroglandular antigen and analogues in melanoma, CD9 expression appears inversely related to metastatic potential of melanoma", Int. J. Cancer, 54:37-43 (1993)	
		K. RADFORD et al, "Suppression of human melanoma cell growth and metastasis by the melanoma-associated antigen CD63 (ME491)", Int. J. Cancer, 62:631-635 (1995)	
		L. SIKORA et al, "Characterization of a novel neuroglandular antigen (NGA) expressed on abnormal human melanocytes", Int. J. Cancer, 39:138-145 (1987)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/810,751
Filing Date	03/26/2004
First Named Inventor	David S. F. Young
Art Unit	1642
Examiner Name	
Attorney Docket Number	2056.039

Sheet	9	of	9
-------	---	----	---

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		S. KENNEL et al, "Monoclonal antibody to rat CD63 detects different molecular forms in rat tissue", Hybridoma, 17(6):509-515 (1998)	
		H. HOTTA et al, "Molecular cloning and characterization of an antigen associated with early stages of melanoma tumor progression", Cancer Research, 48:2955-2962 (June, 1988)	
		H. NIEUWENHUIS et al, "Studies with a monoclonal antibody against activated platelets: evidence that a secreted 53,000-molecular weight lysosome-like granule protein is exposed on the surface of activated platelets in the circulation", Blood, 70(3):838-845 (September, 1987)	
		B. ATKINSON et al, "Monoclonal antibody to a highly glycosylated protein reacts in fixed tissue with melanoma and other tumors", Hybridoma, 4(3):243-255 (1985)	
		G. SAUER et al, "Expression of tetraspanin adaptor proteins below defined threshold values is associated with in vitro invasiveness of mammary carcinoma cells", Oncology Reports, 10:405-410 (2003)	
		H. HOTTA et al, "Overexpression of the human melanoma-associated antigen ME491 patially suppresses in vivo malignant phenotypes of H-ras-transformed NIH3T3 cells in athymic nude mice", Melanoma Research, 1:125-132 (1991)	
		M. KONDOH et al, "Decreased expression of human melanoma-associated antigen ME491 along the progression of melanoma pre-canceroses to invasive and metastatic melanomas", Melanoma Research, 3:241-245 (1993)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.